Cargando…

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

Diabetic nephropathy (DN) affects an estimated 20%–40% of patients with type 2 diabetes mellitus (T2DM). Key modifiable risk factors for DN are albuminuria, anaemia, dyslipidaemia, hyperglycaemia and hypertension, together with lifestyle factors, such as smoking and obesity. Early detection and trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schernthaner, Guntram, Mogensen, Carl Erik, Schernthaner, Gerit-Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230539/ https://www.ncbi.nlm.nih.gov/pubmed/25116004 http://dx.doi.org/10.1177/1479164114542802

Ejemplares similares

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease
por: Lorant, David Peter, et al.
Publicado: (2011)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
por: Schernthaner, Guntram, et al.
Publicado: (2019)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time
por: Hörtenhuber, Thomas, et al.
Publicado: (2013)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
por: Lu, Yang, et al.
Publicado: (2023)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease
por: Schernthaner, Gerit-Holger, et al.
Publicado: (2016)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
por: Mittag‐Roussou, Vasiliki, et al.
Publicado: (2020)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes
por: Zierfuss, Bernhard, et al.
Publicado: (2019)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d4soo2j3skemeb79pd1eeci7up